BCG及其与冠状病毒疾病的关联系统综述:全球健康的争论点?

R. Vijayan, R. Gadodia, S. A. Hassan, A. Choudhry, M. Diaz
{"title":"BCG及其与冠状病毒疾病的关联系统综述:全球健康的争论点?","authors":"R. Vijayan, R. Gadodia, S. A. Hassan, A. Choudhry, M. Diaz","doi":"10.33425/2639-9458.1132","DOIUrl":null,"url":null,"abstract":"Background: COVID-19, a pandemic that started in December 2019 from the city of Wuhan in China. BCG (Mycobacterium Bovis Bacillus Calmette-Guérin) is a live attenuated vaccine used for tuberculosis (TB) that. The BCG vaccine became a part of the ‘National Tuberculosis Control Program (NTCP)’ in India in 1962. The BCG vaccine is given to all children in India, preferably within the first year after birth. However, as per CDC recommendations in the US, BCG is only considered for very select cases, for e.g. children who have a negative TB test and who are continually exposure to adults with TB disease. It induces epigenetic and metabolic alterations at promoter sites of genes encoding inflammatory cytokines such as IL-1,IL-6 and TNF that improve the innate immune response to the subsequent infections by trained immunity. This may be useful in management of COVID-19. Method: We conducted a literature review searching databases like Cochrane, PubMed, Google scholars, CINAHL, LILACS, UpToDate, Scopus, EMBASE, WOS, and Science Direct. We used the following keywords: COVID 19, SARSCoV2 and BCG vaccines. We included case reports, case series and cohort (retrospective and prospective). Results: The global trend suggested an inverse association between BCG vaccination policy and COVID-19 mortality. Countries with current BCG vaccination had lower deaths and was negatively associated with COVID-19 deaths per million Patients with BCG vaccination were more likely to experience myalgia and less likely to require hospital admission. BCG is known to elicit non-specific immune effects through the induction of the innate immune responses and the enhanced production of IL-1β and help combat COVID-19 like respiratory infections. Conclusion: If the BCG vaccine is proven to provide non-specific protection to bridge the gap before a diseasespecific vaccine is developed, this would be an important tool in the response to COVID-19 and future pandemics.","PeriodicalId":93597,"journal":{"name":"Microbiology & infectious diseases (Wilmington, Del.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Systematic Review of BCG and tie-in to coronavirus disease: A Point of Contention for Global Health?\",\"authors\":\"R. Vijayan, R. Gadodia, S. A. Hassan, A. Choudhry, M. Diaz\",\"doi\":\"10.33425/2639-9458.1132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: COVID-19, a pandemic that started in December 2019 from the city of Wuhan in China. BCG (Mycobacterium Bovis Bacillus Calmette-Guérin) is a live attenuated vaccine used for tuberculosis (TB) that. The BCG vaccine became a part of the ‘National Tuberculosis Control Program (NTCP)’ in India in 1962. The BCG vaccine is given to all children in India, preferably within the first year after birth. However, as per CDC recommendations in the US, BCG is only considered for very select cases, for e.g. children who have a negative TB test and who are continually exposure to adults with TB disease. It induces epigenetic and metabolic alterations at promoter sites of genes encoding inflammatory cytokines such as IL-1,IL-6 and TNF that improve the innate immune response to the subsequent infections by trained immunity. This may be useful in management of COVID-19. Method: We conducted a literature review searching databases like Cochrane, PubMed, Google scholars, CINAHL, LILACS, UpToDate, Scopus, EMBASE, WOS, and Science Direct. We used the following keywords: COVID 19, SARSCoV2 and BCG vaccines. We included case reports, case series and cohort (retrospective and prospective). Results: The global trend suggested an inverse association between BCG vaccination policy and COVID-19 mortality. Countries with current BCG vaccination had lower deaths and was negatively associated with COVID-19 deaths per million Patients with BCG vaccination were more likely to experience myalgia and less likely to require hospital admission. BCG is known to elicit non-specific immune effects through the induction of the innate immune responses and the enhanced production of IL-1β and help combat COVID-19 like respiratory infections. Conclusion: If the BCG vaccine is proven to provide non-specific protection to bridge the gap before a diseasespecific vaccine is developed, this would be an important tool in the response to COVID-19 and future pandemics.\",\"PeriodicalId\":93597,\"journal\":{\"name\":\"Microbiology & infectious diseases (Wilmington, Del.)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbiology & infectious diseases (Wilmington, Del.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33425/2639-9458.1132\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbiology & infectious diseases (Wilmington, Del.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33425/2639-9458.1132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:新冠肺炎,一场始于2019年12月的中国武汉市的大流行。BCG(牛分枝杆菌Calmette Guérin)是一种用于治疗结核病的减毒活疫苗。1962年,BCG疫苗成为印度“国家结核病控制计划”的一部分。BCG疫苗适用于印度的所有儿童,最好在出生后的第一年内接种。然而,根据美国疾病控制与预防中心的建议,BCG只被考虑用于非常特殊的病例,例如结核病检测呈阴性的儿童和持续接触患有结核病的成年人的儿童。它在编码炎性细胞因子(如IL-1、IL-6和TNF)的基因的启动子位点诱导表观遗传学和代谢改变,这些细胞因子通过训练免疫来改善对随后感染的先天免疫反应。这可能有助于新冠肺炎的管理。方法:我们对Cochrane、PubMed、Google scholars、CINAHL、LILACS、UpToDate、Scopus、EMBASE、WOS和Science Direct等数据库进行了文献综述。我们使用了以下关键词:2019冠状病毒病、严重急性呼吸系统综合征冠状病毒2型和卡介苗。我们包括病例报告、病例系列和队列(回顾性和前瞻性)。结果:全球趋势表明,BCG疫苗接种政策与新冠肺炎死亡率呈反比。目前接种BCG疫苗的国家死亡率较低,与每百万新冠肺炎死亡呈负相关。接种BCG的患者更有可能出现肌痛,不太可能需要住院治疗。已知BCG通过诱导先天免疫反应和增强IL-1β的产生来引发非特异性免疫效应,并有助于对抗新冠肺炎样呼吸道感染。结论:如果在研制出疾病特异性疫苗之前,BCG疫苗被证明可以提供非特异性保护来弥补这一差距,这将是应对新冠肺炎和未来流行病的重要工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Systematic Review of BCG and tie-in to coronavirus disease: A Point of Contention for Global Health?
Background: COVID-19, a pandemic that started in December 2019 from the city of Wuhan in China. BCG (Mycobacterium Bovis Bacillus Calmette-Guérin) is a live attenuated vaccine used for tuberculosis (TB) that. The BCG vaccine became a part of the ‘National Tuberculosis Control Program (NTCP)’ in India in 1962. The BCG vaccine is given to all children in India, preferably within the first year after birth. However, as per CDC recommendations in the US, BCG is only considered for very select cases, for e.g. children who have a negative TB test and who are continually exposure to adults with TB disease. It induces epigenetic and metabolic alterations at promoter sites of genes encoding inflammatory cytokines such as IL-1,IL-6 and TNF that improve the innate immune response to the subsequent infections by trained immunity. This may be useful in management of COVID-19. Method: We conducted a literature review searching databases like Cochrane, PubMed, Google scholars, CINAHL, LILACS, UpToDate, Scopus, EMBASE, WOS, and Science Direct. We used the following keywords: COVID 19, SARSCoV2 and BCG vaccines. We included case reports, case series and cohort (retrospective and prospective). Results: The global trend suggested an inverse association between BCG vaccination policy and COVID-19 mortality. Countries with current BCG vaccination had lower deaths and was negatively associated with COVID-19 deaths per million Patients with BCG vaccination were more likely to experience myalgia and less likely to require hospital admission. BCG is known to elicit non-specific immune effects through the induction of the innate immune responses and the enhanced production of IL-1β and help combat COVID-19 like respiratory infections. Conclusion: If the BCG vaccine is proven to provide non-specific protection to bridge the gap before a diseasespecific vaccine is developed, this would be an important tool in the response to COVID-19 and future pandemics.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信